Please login to the form below

Not currently logged in

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Novo Nordisk headquartersZiylo could help it stay ahead in key insulin franchise

Pfizer signs mRNA flu vaccine deal with BioNTech

Pharma giant will take on development and commercial responsibility for candidates

After Cohen payment scandal, Novartis unveils new ethics chief

MoosmayerNew 'risk and compliance' leader has increased powers

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Gene therapy trend grows, new rival for Fabrazyme

Human Cell Atlas gets new UK funding

ResearchThe project will allow researchers to define characteristics of single cell types

Spark sputters on haemophilia A gene therapy safety scare

Investors compare data unfavourably with BioMarin rival

Almirall acquires Allergan’s dermatology portfolio for $650m

Almirall SpainThe pharma group buys four products along with Allergan's first-in-class antibiotic Seysara

Immunology keeps Shire figures solid as Takeda takeover nears

TakedaShire’s sales increased by 6% to $3.81bn

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...